Cero Therapeutics Holdings, Inc. (CERO)
CERO is quoted over the counter, not listed on an exchange. Cero Therapeutics Holdings, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | CERO, quoted over the counter |
| SEC CIK | 0001870404 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Business address | South San Francisco, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued." | 10-Q 2026-11-13 |
| Cash and burn | $863K cash; operating cash flow -$1.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 83,309,742 (2026-11-13); 21,102,671 a year earlier. | Cover page 2026-11-13 |
| Reverse splits, 3 years | 2; latest 1-for-20 on 2025-06-13 | Source 2025-06-13 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-02-03 |
| Delisting | 25-NSE filed | 25-NSE 2026-07-13 |
| Auditor | Salberg & Company, P.A., Boca Raton, Florida, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-02-13 |
| Late filings, 12 months | 2 NT notices | NT 10-K 2026-04-01 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.0M | -$7.9M | $863K | $2.2M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$5.9M | $2.8M | $857K | $137K | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$4.5M | Not filed | $1.7M | No debt tags | Needs four quarters | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | Not filed | -$4.9M | Not filed | $1.9M | No debt tags | Needs four quarters | 10-Q 2025-11-19 |
| Q2 2025 2025-06-30 | Not filed | -$5.4M | Not filed | $3.2M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$5.1M | Not filed | $5.1M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q3 2024 2024-09-30 | Not filed | -$4.2M | Not filed | $3.4M | No debt tags | Needs four quarters | 10-Q 2025-11-19 |
| Q2 2024 2024-06-30 | Not filed | -$2.4M | Not filed | $3.6M | No debt tags | Needs four quarters | 10-Q 2025-11-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-08-14 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-10-07 |
| Latest proxy | DEFA14A | 2025-12-02 |
Source: SEC EDGAR submissions feed, 446 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier